Ventum Cap Mkts Upgrades Medexus Pharmaceuticals (TSE:MDP) to Strong-Buy

Medexus Pharmaceuticals (TSE:MDP) was upgraded by stock analysts at Ventum Cap Mkts to a “strong-buy” rating in a note issued to investors on Wednesday, Zacks.com reports.

Medexus Pharmaceuticals Stock Up 1.2 %

Shares of MDP stock opened at C$1.74 on Wednesday. The stock has a fifty day moving average of C$1.67 and a 200 day moving average of C$1.87. Medexus Pharmaceuticals has a 52 week low of C$1.30 and a 52 week high of C$3.53. The firm has a market capitalization of C$42.56 million, a price-to-earnings ratio of 4.35 and a beta of 1.82.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.